Non-transplant patients with haematologic malignancies have better survival outcome than recipients of haematopoietic stem cell transplant (HSCT) after admission to intensive care unit (ICU).

Patients with haematological malignancies admitted to ICU have a high mortality rate. Identifying predictors of mortality and survival may be useful for clinical decision making and can help to improve survival. The differences in mortality rate and other outcomes between recipients of HSCT and non-transplant haematologic patients admitted to the ICU have been poorly studied.